{
    "data": [
        {
            "id": "4396098",
            "type": "article",
            "attributes": {
                "publishOn": "2020-12-24T06:54:55-05:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: Why Now Is A Great Time To Buy This Cash Cow",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105703",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "306214",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4396098-amgen-why-now-is-great-time-to-buy-this-cash-cow"
            }
        },
        {
            "id": "4391687",
            "type": "article",
            "attributes": {
                "publishOn": "2020-11-26T09:10:40-05:00",
                "isLockedPro": false,
                "commentCount": 81,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "You Need To Look At Amgen - Right Now",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105093",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "302507",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4391687-you-need-to-look-amgen-right-now"
            }
        },
        {
            "id": "4379750",
            "type": "article",
            "attributes": {
                "publishOn": "2020-10-19T11:37:13-04:00",
                "isLockedPro": false,
                "commentCount": 18,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen Is Headed For $220, But It Could Be Worth $400",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103213",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "296844",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4379750-amgen-is-headed-for-220-be-worth-400"
            }
        },
        {
            "id": "4378486",
            "type": "article",
            "attributes": {
                "publishOn": "2020-10-11T04:23:32-04:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen - Slower Growth, Pipeline Setback, Non-Demanding Valuation",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "295818",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4378486-amgen-slower-growth-pipeline-setback-non-demanding-valuation"
            }
        },
        {
            "id": "4375302",
            "type": "article",
            "attributes": {
                "publishOn": "2020-09-20T06:08:40-04:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: Growing At A Reasonable Price",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105703",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "293121",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4375302-amgen-growing-reasonable-price"
            }
        },
        {
            "id": "4373314",
            "type": "article",
            "attributes": {
                "publishOn": "2020-09-09T14:12:43-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: Massive Pharmaceutical Strength",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "291537",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4373314-amgen-massive-pharmaceutical-strength"
            }
        },
        {
            "id": "4372743",
            "type": "article",
            "attributes": {
                "publishOn": "2020-09-05T09:00:38-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen Still A Buy After Joining The Dow",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "291228",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4372743-amgen-still-buy-after-joining-dow"
            }
        },
        {
            "id": "4361846",
            "type": "article",
            "attributes": {
                "publishOn": "2020-07-29T13:27:58-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen's Earnings, And Other News: The Good, Bad And Ugly Of Biopharma",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "286033",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4361846-amgens-earnings-and-news-good-bad-and-ugly-of-biopharma"
            }
        },
        {
            "id": "4356282",
            "type": "article",
            "attributes": {
                "publishOn": "2020-06-29T22:24:45-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: A Diversified Biotech Giant For Your Income Portfolio",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103182",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "281720",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4356282-amgen-diversified-biotech-giant-for-your-income-portfolio"
            }
        },
        {
            "id": "4352470",
            "type": "article",
            "attributes": {
                "publishOn": "2020-06-08T06:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "ChemoCentryx: Avacopan's Attractive Value Proposition",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103487",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "267523",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4352470-chemocentryx-avacopans-attractive-value-proposition"
            }
        },
        {
            "id": "4349735",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-23T11:50:33-04:00",
                "isLockedPro": false,
                "commentCount": 38,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: Why I'm Ready To Buy This Biotech",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "59101",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "276595",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4349735-amgen-why-ready-to-buy-this-biotech"
            }
        },
        {
            "id": "4348625",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-19T04:21:59-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Deciphera's GIST Approval, And Other News: The Good, Bad And Ugly Of Biopharma",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "276164",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4348625-decipheras-gist-approval-and-news-good-bad-and-ugly-of-biopharma"
            }
        },
        {
            "id": "4340195",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-27T10:12:45-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen Is Attractively Valued",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102764",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "272482",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4340195-amgen-is-attractively-valued"
            }
        },
        {
            "id": "4339346",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-23T06:21:14-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen A Buy On Otezla Revenue",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "271832",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4339346-amgen-buy-on-otezla-revenue"
            }
        },
        {
            "id": "4334226",
            "type": "article",
            "attributes": {
                "publishOn": "2020-03-25T16:48:46-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: A Healthy And Defensive Pick In COVID-19 Times",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102293",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "267363",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4334226-amgen-healthy-and-defensive-pick-in-covidminus-19-times"
            }
        },
        {
            "id": "4320308",
            "type": "article",
            "attributes": {
                "publishOn": "2020-01-30T15:26:02-05:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "ChemoCentryx: An Intriguing Rare Disease Player In 2020",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102293",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "258788",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4320308-chemocentryx-intriguing-rare-disease-player-in-2020"
            }
        },
        {
            "id": "4319988",
            "type": "article",
            "attributes": {
                "publishOn": "2020-01-29T19:21:40-05:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: At All-Time Highs, I'm Cautiously Optimistic",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "258200",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4319988-amgen-all-time-highs-cautiously-optimistic"
            }
        },
        {
            "id": "4319977",
            "type": "article",
            "attributes": {
                "publishOn": "2020-01-29T18:10:38-05:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: Needs To Pop After Earnings On Thursday",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24823",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "258587",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4319977-amgen-needs-to-pop-after-earnings-on-thursday"
            }
        }
    ]
}